Navigation Links
Genedata Announces New Solution for Efficient Analysis of High-Throughput Automated Patch Clamp Experiments

Genedata, a leading provider of advanced software solutions for R&D, today announced the general availability of a new solution for the automated analysis of Automated Patch Clamp (APC) data. The innovative software package has been developed in close collaboration with AstraZeneca and is available as part of Genedata Screener for Ion Channel Screening. New functionality added to the existing Screener APC package provides further in-depth characterization of compound effects on key ion channels, which are important for regulating cardiac action potential. AstraZeneca scientists will discuss the new analysis solution in a webinar - “A New Analysis Capability to Improve Assessment of Cardiac Liability in High Throughput Electrophysiology” (June 7, 2017).

Early indications of potential safety issues early in the R&D process minimize the risk of product liabilities and patient health issues. Modern APC technology provides scalable functional measurements of ion channels and, if analyzed properly, quickly yields qualitative data on large numbers of compounds. “We collaborated with Genedata to develop an integrated, high-throughput APC analysis solution. This is key to characterizing and ranking compounds alongside other key data as part of the drug discovery process,” noted Matt Bridgland-Taylor, associate principal scientist at AstraZeneca’s Innovative Medicines & Early Discovery Biotech Unit.

The high-throughput APC assays developed by AstraZeneca and supported by Genedata Screener are fundamental in eliminating key liabilities and designing strong leads in the drug discovery process. The solution increases specificity and throughput, which ultimately saves time, reduces risk, and improves R&D productivity.

Full APC Data Analysis with Genedata Screener
AstraZeneca uses the Nanion SyncroPatch 384PE system to obtain physiological ion channel data. Nanion is a partner in the Genedata Ready-to-Run program and closely works with Genedata to serve joint customers with a smooth integration of its hardware with Genedata Screener and optimized data analysis workflows for APC.

To optimize analysis of the Nanion SyncroPatch 384PE instrument’s high volume of complex current traces, new methods for automated data QC and quantifying the onset of effect to identify slow onset compounds were added to Genedata Screener. The resulting solution reads raw binary data directly from the instrument into Genedata Screener and enables:

  • Complete processing from raw data (sweeps) to cumulated compound results.
  • Systematic and early testing of compounds key cardiac channels (e.g. hERG potassium channel) in cumulative curve format.
  • Kinetic determination of the onset of effect as a parameter and the automatic identification of slow onset blockers previously undetected.
  • Automated analysis, annotation, and reporting of APC results on the same software platform used for all other screens at AstraZeneca.

Genedata Screener for Ion Channel Screening is a generic solution that works with a broad range of APC instruments. It incorporates cutting-edge capabilities such as: analysis of titration data in multiple scenarios; sweep normalization for cumulative curves; filtering and masking; current/voltage trace visualization; and robust quality metrics.

“The new developments have enhanced our ability to analyze and interrogate complex datasets for hERG and other key ion channels involved in the regulation of cardiac action potential, and substantially increases our throughput,” said Ana Teixeira, informatics analyst with AstraZeneca R&D who was responsible for the co-development project.

“Our collaboration with AstraZeneca exemplifies our efforts to deliver solutions that improve research productivity and efficiency,” noted Dr. Othmar Pfannes, CEO of Genedata. “With this latest addition to Genedata Screener, we enable our customers to systematically run affordable safety screens early in the lead discovery stage. The solution uses APC instruments to their full potential, and thus increases productivity and creates new efficiencies for pharmaceutical R&D.”

Editorial Note: AstraZeneca Webinar
Title: A New Analysis Capability to Improve Assessment of Cardiac Liability in High Throughput Electrophysiology
Date: June 7, 2017
Time: 9:00 am EDT

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
Follow Genedata on LinkedIn

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Expressionist 11.0 Released at ASMS 2017
2. Genedata Celebrates 20 Years of Bioinformatics Innovations at Bio-IT World
3. Leading Pharma and Research Organizations to Attend Genedata Screener Global User Group Meetings
4. Genedata Expands Into United Kingdom
5. SLAS2017 - Genedata Announces BMG LABTECH, Creoptix and TTP Labtech as New Ready-to-Run Partners
6. New Genedata Screener® APC Functionality and Integration with Nanion SyncroPatch 384PE at SLAS2017
7. Genedata Launches Data Science Services for Precision Medicine
8. Genedata Partners with Crescendo Biologics on Next-generation Immuno-oncology and ADC Programs
9. F-star Selects Genedata Biologics for Immuno-Oncology Therapeutics Discovery
10. Genedata Expands Partnership with MorphoSys to Support New Antibody Libraries and Developability Assessment
11. Genedata Announces the Release of Genedata Bioprocess - New Workflow Platform for Biopharmaceutical Development
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):